Targeting ADPN pathways through lifestyle or pharmacological approaches may mitigate obesity‐related complications, highlighting its role in metabolic homeostasis and CVD prevention. This evidence concerns the gene ADIPOQ and obesity due to melanocortin 4 receptor deficiency.